Pharmaceutical sponsor
CSPC Ouyi Pharmaceutical Co., Ltd. Clinical Trials
Studies where CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 10Respiratory Syncytial Virus Infections
Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of SYH2066 tablets in adult patients with RSV infection.
- Trial name
- NCT07881991
- Testing
- SYH2066
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
T2DM (Type 2 Diabetes Mellitus)
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
This study is a multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study aimed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SYH2069 Injection in…
- Trial name
- NCT07796477
- Testing
- SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Postoperative Pain
Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.
This is a randomized, double-blind, active drug- and placebo-controlled, dose-escalation clinical study conducted in patients scheduled to undergo abdominal surgery.
- Trial name
- NCT07519109
- Testing
- SYH9089 injection, Ropivacaine hydrochloride, 0.9 % sodium chloride
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Primary Hyperlipidemia
A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid
This trial is a multicenter randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of Bempedoic Acid Tablets in patients with hyperlipidemia not adequately controlled by Statins.
- Trial name
- NCT07623915
- Testing
- Bempedoic Acid Tablet
- Volunteers
- 222 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Severe Alopecia Areata
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.
- Trial name
- NCT06562894
- Testing
- SYHX1901
- Volunteers
- 156 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD)
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial, aim to evaluate the efficacy and safety of dextromethorphan and bupropion sustained-release tablets in Chinese adult patients with major depressive…
- Trial name
- NCT06958692
- Testing
- Dextromethorphan and Bupropion Sustained-Release Tablets
- Where
- China
- Volunteers
- 388 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Moderate to Severe Plaque Psoriasis
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT06943950
- Testing
- SYHX1901
- Volunteers
- 500 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Pancreatic Cancer
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal…
- Trial name
- NCT06571461
- Testing
- Liposomal Irinotecan, Oxaliplatin, S-1
- Volunteers
- 408 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011
- Trial name
- NCT06354114
- Testing
- SYHX2011
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.